1. High-expenditure Medicare drugs often qualified for Orphan Drug Act incentives designed to encourage the development of treatments for rare diseases Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2021 Subject(s): Drug Development -- legislation & jurisprudenceGovernment RegulationMedicare Part B -- economicsMedicare Part D -- economicsOrphan Drug Production -- economicsUnited StatesUnited States. Department of Health and Human Services
